{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:57:41Z","timestamp":1792519061234,"version":"4.5.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004328","name":"Genentech Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009164","name":"Moffitt Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009164","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ijrobp.2025.05.003","type":"journal-article","created":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T11:43:20Z","timestamp":1747223000000},"page":"298-305","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Atezolizumab and Stereotactic Body Radiation in Metastatic, Recurrent, or Persistent Cervical Cancer: Results From a Phase 2 Multi-Institutional Study"],"prefix":"10.1016","volume":"125","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3331-1529","authenticated-orcid":false,"given":"Kamran A.","family":"Ahmed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison M.","family":"Quick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye Sook","family":"Chon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Yi","family":"Chern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Bixel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youngchul","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiannong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E.","family":"Montejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin A.","family":"Dowell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sungjune","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel C.","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesar A.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ardeshir","family":"Hakam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilin","family":"Rosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Shafique","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mian M.","family":"Shahzad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert M.","family":"Wenham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2025.05.003_bib0001","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/S0140-6736(17)31607-0","article-title":"Bevacizumab for advanced cervical cancer: Final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (gynecologic oncology group 240)","volume":"390","author":"Tewari","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2025.05.003_bib0002","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.18.01265","article-title":"Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: Results from the phase II KEYNOTE-158 study","volume":"37","author":"Chung","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.05.003_bib0003","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa2112435","article-title":"Pembrolizumab for persistent, recurrent, or metastatic cervical cancer","volume":"385","author":"Colombo","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2025.05.003_bib0004","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(24)00317-9","article-title":"Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-CX11\/GOG-3047\/KEYNOTE-A18): A randomised, double-blind, phase 3 clinical trial","volume":"403","author":"Lorusso","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2025.05.003_bib0005","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/S0140-6736(24)01808-7","volume":"404","author":"Lorusso","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2025.05.003_bib0006","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1200\/JCO.20.00818","article-title":"Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: Long-term results of the SABR-comet phase II randomized trial","volume":"38","author":"Palma","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.05.003_bib0007","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1001\/jamaoncol.2024.1796","article-title":"Stereotactic ablative radiotherapy for gynecological oligometastatic and oligoprogessive tumors","volume":"10","author":"Donovan","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijrobp.2025.05.003_bib0008","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1172\/JCI67313","article-title":"Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice","volume":"124","author":"Deng","year":"2014","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ijrobp.2025.05.003_bib0009","doi-asserted-by":"crossref","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","article-title":"Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria","volume":"15","author":"Wolchok","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2025.05.003_bib0010","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001126","article-title":"Phase II study of atezolizumab in combination with bevacizumab in patients with advanced cervical cancer","volume":"8","author":"Friedman","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ijrobp.2025.05.003_bib0011","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.1200\/JCO.23.00914","article-title":"First-line pembrolizumab + chemotherapy versus placebo + chemotherapy for persistent, recurrent, or metastatic cervical cancer: Final overall survival results of KEYNOTE-826","volume":"41","author":"Monk","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.05.003_bib0012","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(23)02405-4","article-title":"Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATCC): A randomised, open-label, phase 3 trial","volume":"403","author":"Oaknin","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2025.05.003_bib0013","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/modpathol.2016.221","article-title":"Expression of PD-L1 and presence of CD8-positive T cells in pre-treatment specimens of locally advanced cervical cancer","volume":"30","author":"Enwere","year":"2017","journal-title":"Modern Pathol"},{"key":"10.1016\/j.ijrobp.2025.05.003_bib0014","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13000-017-0631-6","article-title":"Programmed death-ligand 1 (PD-L1) is expressed in a significant number of the uterine cervical carcinomas","volume":"12","author":"Reddy","year":"2017","journal-title":"Diagn Pathol"},{"key":"10.1016\/j.ijrobp.2025.05.003_bib0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0263615","article-title":"Programme death ligand 1 expressions as a surrogate for determining immunotherapy in cervical carcinoma patients","volume":"17","author":"Omenai","year":"2022","journal-title":"PLOS ONE"},{"key":"10.1016\/j.ijrobp.2025.05.003_bib0016","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.ijrobp.2022.05.013","article-title":"Combination of SABR with anti-PD-1 in oligoprogressive non-small cell lung cancer and melanoma: Results of a prospective multicenter observational study","volume":"114","author":"Chicas-Sett","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.05.003_bib0017","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nature14292","article-title":"Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer","volume":"520","author":"Twyman-Saint Victor","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.ijrobp.2025.05.003_bib0018","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1200\/JCO.20.00290","article-title":"Randomized phase II trial of nivolumab with stereotactic body radiotherapy versus nivolumab alone in metastatic head and neck squamous cell carcinoma","volume":"39","author":"McBride","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.05.003_bib0019","doi-asserted-by":"crossref","first-page":"A2","DOI":"10.1136\/ijgc-2022-igcs.3","article-title":"Durvalumab, in combination with and following chemoradiotherapy, in locally advanced cervical cancer: Results from the phase 3 international, randomized, double-blind, placebo-controlled calla trial","volume":"32","author":"Monk","year":"2022","journal-title":"Int J Gyn Canc"},{"key":"10.1016\/j.ijrobp.2025.05.003_bib0020","doi-asserted-by":"crossref","first-page":"7015","DOI":"10.1038\/s41467-022-34676-w","article-title":"Elective nodal irradiation mitigates local and systemic immunity generated by combination radiation and immunotherapy in head and neck tumors","volume":"13","author":"Darragh","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.ijrobp.2025.05.003_bib0021","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1056\/NEJMoa2112187","article-title":"Survival with cemiplimab in recurrent cervical cancer","volume":"386","author":"Tewari","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2025.05.003_bib0022","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1470-2045(21)00056-5","article-title":"Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (INNOVATV 204\/GOG-3023\/ENGOT-CX6): A multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Coleman","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2025.05.003_bib0023","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1200\/JCO.2017.76.2229","article-title":"Safety and clinical activity of pembrolizumab and multisite stereotactic body radiotherapy in patients with advanced solid tumors","volume":"36","author":"Luke","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.05.003_bib0024","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.ijrobp.2022.06.068","article-title":"Predictors of pneumonitis in combined thoracic stereotactic body radiation therapy and immunotherapy","volume":"114","author":"Korpics","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.05.003_bib0025","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1093\/annonc\/mdv622","article-title":"Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-pd-1 therapy","volume":"27","author":"Ahmed","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2025.05.003_bib0026","doi-asserted-by":"crossref","first-page":"5379","DOI":"10.1158\/1078-0432.CCR-09-0265","article-title":"Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-ctla-4 antibody","volume":"15","author":"Dewan","year":"2009","journal-title":"Clin Cancer Res"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301625004468?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301625004468?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T08:34:04Z","timestamp":1782030844000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301625004468"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0360301625004468"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2025.05.003","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Atezolizumab and Stereotactic Body Radiation in Metastatic, Recurrent, or Persistent Cervical Cancer: Results From a Phase 2 Multi-Institutional Study","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2025.05.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}